1. Medtech Insight
  2. >>Geography

Why NICE Is Building The Medtech Innovation Plane As It Flies

 
• By Eliza Slawther

England’s NICE is ditching the rulebook in favor of “failing forward faster” when it comes to tackling medtech innovations. The organization’s interim director of medical technology says this approach mirrors the entrepreneurial nature of the medtech, diagnostics and digital sectors.

Plane
• Source: Shutterstock

The National Institute for Health and Care Excellence (NICE) is most well-known for its cost-effectiveness assessments of pharmaceutical goods and generation of clinical guidelines, which are used to guide health care reimbursement in England and Wales. Although the organization also provides guidance and assessments in the medtech field, this has historically taken a backseat to its other activities.

This may be set to change, as NICE’s chief executive Sam Roberts recently highlighted devices, diagnostics and digital as three...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Liquid Biopsy Startup Mursla Bio Launches AI Precision Medicine Platform

 
• By Natasha Barrow

The new AI Precision Medicine platform supports the company’s flagship product, EvoLiver, which received US FDA breakthrough device designation in April.

Prix Galien Spotlights Mental Health ‘Renaissance’ But Systemic Hurdles Persist

 
• By Natasha Barrow

Experts at the Prix Galien UK Forum discussed the future of mental health innovation, emphasizing the important roles of digital solutions, diagnostic biomarkers and community involvement.

Increasing Safety Concerns Spur Scrutiny of Device Plastics Use

 
• By Elizabeth Orr

With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.